HANSEN GWENN (Chief Scientific Officer) sold 4.5% of their position (5.39K shares) of NURIX THERAPEUTICS, INC. on the open market
Open‑market sale worth $107.9K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 6/25/2026ACC: 0001817160-26-000010
Officer· Chief Scientific Officer
Since Jul 2020
-5.39K
Net shares
Net seller
$107.9K
Total sold
1
Open market trades
0B · 1S
1
Total transactions
5.39K disposed
Non-Derivative Transactions1
Common Stock
Direct
Shares
−5.39K
Price / share
$20.00
Trade value
$107.88K
% of position
4.5%
6/25/2026
120.40K→115K
Total
Net shares
−5.39K
Net value
-$107.88K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/25/2026 | S · Sale | −5.39K | $20.00 | $107.88K | 4.5% | 120.40K | 115K |
| Total | −5.39K | -$107.88K | ||||||
Derivative Transactions0
No derivative transactions reported